Graham Combe

How do growth factors produce cell division? Growth factors promote cell proliferation by initiating a chain of events when they bind to their receptors, which ripple through the cell. Our latest blog article explains these events. https://lnkd.in/eSS-qsjS

17

At last week's #TechBioUK the BioIndustry Association (BIA) launched its 'TechBio: UK leads innovation frontier' report in collaboration with Citeline. The report delves into the latest advancements driven by AI and data-driven approaches, which are revolutionising drug discovery, diagnostics and personalised medicine. Access it here - https://ow.ly/YJOy50TNsoF #AI #Data #DrugDiscovery

3

Antibody purification is an essential step in producing high-quality antibodies, but there's no one 'right' approach. At evitria, we offer a range of purification services designed to meet the diverse needs of our clients' projects. This includes offering alternative resins to aid protein capture for antibodies without a strong affinity to Protein A. Find out what these are and the methods we use for protein polishing in our blog. If you have any questions, please message me or the rest of the team. With evitria, your project is in safe hands. #AntibodyManufacturing #Antibodies #AntibodyPurification #ProteinCapture

14

This is such an important subject and a big thanks to British In Vitro Diagnostics Association (BIVDA) for raising it at a Parliamentary Reception this week. Getting innovations into the NHS is challenging, especially for SMEs who have limited resources and significant pressures from their investors to get sales. One of the unfortunate consequences of this is that SMEs are forced to focus their efforts on larger international markets with quicker pathways to adoption, and UK patients cannot access homegrown innovations. Surely there must be a way to reduce the barriers to adoption to ensure British innovations are available in their home market first? #skincancer #melanoma #diagnostic # innovation #AMBLor

24

1 Comment

Want to catch bacterial contamination early in your CHO cell cultures? Aber Instruments Ltd's webinar (link below!) explores how conductivity & dielectric spectroscopy can help with real-time monitoring & process automation. https://lnkd.in/eQPxdiGj #WebinarAlert #bioprocess #biotechnology #ProcessAutomation #CellCulture #ContaminationDetection #learning

4

Kairos Biotech Ltd are pleased to announce they have received follow-on funding of €1m from Dutch entity EchiumBio Holding BV.   Kairos Biotech management comprises CEO & founder, Dr Mike Bunce, R&D director Ben Passey, Senior Scientist Hayley Hogan and Investor Director Dr Wietse Mulder.   The transaction was executed with legal support from Herke van Hulst and Angela Saldanha at Osborne & Clarke in Amsterdam and Catherine Williams from Keystone Law in London.    The follow-on investment came after the company achieved significant milestones in developing its novel molecules for transplant diagnostics and applications in targeted immunotherapy.   Our approach in transplantation   Successful kidney and other solid organ transplants need to avoid immunological rejection to succeed. Unfortunately, many patients have pre-formed anti-donor T and B cells that restrict the opportunities for transplant. Some patients may wait years for a transplant opportunity due to deleterious anti-donor immunological responses.    Kairos Biotech aims to improve transplant success by developing small molecules that are suitable for both improving diagnostics, and molecularly enhanced to modulate or remove immunological anti-donor responses. We will demonstrate that these ‘designer immunosuppressive molecules’ can interfere and remove the anti-donor responses in a highly-specific and possibly permanent way. This transplant tolerance is expected to be highly beneficial for the transplant of highly sensitized patients. This will enable shorter waiting times for transplant, and potentially improved transplant survival.

62

6 Comments

https://lnkd.in/eWsz7CcU With over 60 references, The Neospora Antibody Test Kit from VMRD, Inc. and available from 2BScientific Ltd. employs a competitive ELISA technique to detect the presence of Neospora caninum antibodies in serum samples from cattle. 🐝 Exceptional Precision: Evidenced through sensitivity and specificity assessments, ensuring dependable identification of both positive and negative sera. 🐝 Distinct Discrimination: 5% of sera registered within ±5% of the cut-off value, underscoring exact differentiation between positive and negative samples. 🐝 Streamlined Screening: Streamlines the examination of extensive sample sets, as evidenced by the analysis of 4,323 sera with unknown serologic statuses. 🐝 Robust Confidence: Minimal overlap near the cut-off value inspires assurance in the kit's accuracy. For your own research reagents, get in contact at sales@2bscientific.com with any queries about this ELISA, our products, or anything concerning life science! #petwelfare #neospora #hereforyou

5

The market for bispecific antibodies is growing, creating opportunities for pharma and biotech companies. However, an understanding of bsAbs is required before organisations can start their journey. In this blog post, our own Desmond Schofield explores what bsAbs are, their history, and future prospects for the sector. If you're ready to start exploring the therapeutic potential of these antibodies, the later sections detail how evitria can support you or you can simply get in touch with our team today. #Antibodies #BispecificAntibodies #Biotech #Biopharma

18

1 Comment

World’s Largest Proteome Study is leveraging Olink Technology. The UK Biobank Pharma Proteomics Project will analyse over 600,000 samples to map disease-associated protein levels and advance biomarker discovery. The study is a collaboration between UK Biobank and 14 leading biopharmaceutical companies. It comes as no surprise that Olink has been chosen for this monumental study, as Olink stands as the undisputed world leader in the affinity proteomics field. With over 19,000 researchers worldwide already using UK Biobank data, this initiative is poised to have a major impact. Massive proteomics studies such as the UK Biobank Pharma Proteomics Project are transforming our understanding of health and disease by revealing how proteins influence biological processes. These efforts are paving the way for earlier diagnoses, better treatments, and precision medicine — helping to improve lives and reduce the burden of disease worldwide. Explore how our Olink services can accelerate your research: www.bioxpedia.com #Proteomics #ClinicalResearch #PrecisionMedicine #LifeSciences #DrugDevelopment

35

Looking forward to attending the LSX Investival Showcase in London next week to meet up with familiar faces as well as making new connections. Please do get in touch if you’d like to meet there to discuss the latest developments for maraciclatide, including the latest findings from our DETECT endometriosis Phase II study and the start of our Phase III trials in inflammatory arthritis. #endometriosis #womenshealth #inflammatoryarthritis #molecularimaging #diagnosticimaging #medicalimaging #precisionmedicine #nuclearmedicine

12

ALS Community, Scientists and Researchers - Look out! At Axol Bioscience we continue to build tools, infrastructure and assays that support “Better Human Disease Modeling” decrease time and risk of Drug Discovery in ALS and ultimately improve patients lives. Massive THANK-YOU to the Scottish Government for their continued support of Axol Bioscience through the awarding of this SMART Grant. The key objectives of this project are to: 1. Develop a quality manufacturing system for iPSC-derived ALS relevant cell types 2. Characterise and validate the cells using ALS relevant end points; TDP43 aggregation, Neurofilament Light elevation and Cryptic Exon Sequencing 3. Develop and characterise an ALS co-culture model which includes motor neurons, microglia and astrocytes 4. Commercialise an easy-to-use model system to drive forward ALS drug discovery The grant is part of a broader push to scale the impact of Scotland’s innovation strengths, with a focus on projects that contribute to economic transformation. It's great that iPSCs have been recognised by the Scottish Enterprise to be a part of this cause. To read more about the project and what we plan to achieve with this grant, head over to our website to read our new news piece: https://hubs.la/Q02-Fx3s0 If you would like to ask us a question or discuss this recent news with us, contact us at operations@axolbio.com. Stay tuned over the comings months for validation data and new assays! Best Liam see www.axolbio.com #motorneurondisease #ALS #drugdiscovery #drugdevelopment #biotech #stemcells #ipscs #cellculture #neuromuscular #CNS #neuroscience #pharma #axolbioscience #alsmndsymp

40

2 Comments

An #exciting #hybrid #event coming to you from Genomes.io in partnership with Opportunity North East Limited #BioHub and BlockStart Scotland! 🌟 Join #DeSci Scotland on the 13th of June 2024 at Opportunity North East Limited #BioHub or online! What is #DeSci #Scotland? 🤔 #DeSci Scotland aims to dive into the world of data science to explore the latest trends and technologies with academic and industry experts. This event is focusing on the concept of Decentralised Science (DeSci), a narrative using blockchain technology to ensure that healthcare data is queried in such a way that it benefits all stakeholders involved! This event is targeting #datascientists, #molecularbiologists, #geneticists and anyone curious about the field! More details and the registration link can be found in the #attached post! 🤩 (Please not that this link is for anyone planning to join remotely). Please get in touch if you would like to attend in-person! 😊 #genomics #genomicdata #datascience #genetics #humangenomics #biotechnology ONE Life Sciences

17

2 Comments

https://lnkd.in/e83BGiDZ Immune Checkpoint Proteins available at 2BScientific Ltd. from our trusted supplier Bio X Cell Immune checkpoint proteins are regulators of the immune system that prevent foreign antigens and preferably the host’s immune cells from attacking, thereby regulating self-tolerance, immune homeostasis and prevent autoimmunity. The checkpoint proteins can send two types of signals to express these immune responses: 🐝 Co-stimulatory checkpoints deliver positive signals to T cells following their binding to ligands and receptors on antigen-presenting cells (APCs). They can stimulate immune responses, including CD27, CD40, OX40, GITR, 4-1BB, CD28, ICOS and many more. 🐝 Co-inhibitory checkpoints deliver negative signals to T cells upon interaction with their counterparts on the APCs. They can inhibit immune responses, including PD1, PD-L1, CTLA-4, VISTA, CD155/TIGIT, TIM-3, and more. #2BScientific #herefor you #bioxcell #immunecheckpointproteins

15

https://lnkd.in/eMnPdwZs Read the latest blog on the comparison of molecular detection Techniques: SYBR Green Vs. TaqMan written by our expert Product Manager John Probert at 2BScientific Ltd. #TaqMan and #SYBR Green #PCR techniques are critical for research in molecular biology, driving advancements in investigations and diagnostics. Here’s why they're essential: Gene Expression Analysis and Biomarker Detection: SYBR Green PCR for screening, followed by TaqMan PCR for precise quantification and validation. Microbial Detection and Oncology: SYBR Green PCR for broad screening, TaqMan PCR for accurate quantification of specific targets. Epigenetics Studies, Pharmacogenomics, and Personalised Medicine: SYBR Green PCR's early assessment complements TaqMan PCR's precision, aiding informed treatment decisions. Check out the detailed article from 2BScientific covering the utilisation of TaqMan and SYBR Green, along with our selection of superior research reagents suitable for PCR and various research applications. #hereforyou #2bscientific #molecular

7

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

1

 Introducing CellRepo, the first Version Control System for Synthetic Biology. GitLife Biotech, a pioneering UK-based biotech company, is on a mission to set the global standard in the management of provenance, biosafety, biosecurity and integrity of biological assets. Their innovative solutions provide essential infrastructure to enhance reproducibility and traceability in engineering biology. These innovations collectively aim to enable robust rights management and set new industry standards, reinforcing the security and authenticity of biological materials. Their integrated bio-digital version control platform, the only one of its kind, will help shape the future of synthetic biology by ensuring it remains a secure and reliable field.  OVERVIEW GitLife Biotech is bringing fundamental infrastructure to the synthetic biology industry through its two core innovations in version control and biosecurity The Company’s vision is to enable the global community to safely and seamlessly; develop, commercialise, deploy and trace engineered biological assets. In the field of synthetic biology, the process of strain engineering has unique  challenges due to the numerous iterative attempts to achieve desired outcomes. Ensuring meticulous documentation of cell line changes is crucial to establish robust provenance of bioengineered assets, mitigating the risk of data loss and safeguarding project integrity. Additionally, while patenting services protect ownership rights, these can only be submitted at the end of development and are not physically linked to the subject strain. As the sector grows, an end to end solution, aligned to the regulatory framework, that adequately supports secure data management and cataloguing the digital information generated throughout the development process is essential.  One that enables better traceability and robust proof ownership.  GitLife Biotech's pioneering version control system, CellRepo, addresses these challenges by enabling the digital documentation of a strain's identity, ownership, and construction. When combined with its unique DNA barcodes, linking cell samples with their digital records, organisations can more robustly protect and commercialise their assets. This combination ensures proof of ownership and provenance and facilitates the safe implementation of synthetic biology across industries.  See buff.ly/3UcDDtb GITFLIFE BioTech is portfolio company of XSS Capital. If you are interested in this funding round please DM me for more info. Join our mailing list at buff.ly/4cd2OCo

3